Previous 10 | Next 10 |
Thinly traded nano cap Akari Therapeutics ( AKTX +5.9% ) is up on average volume in reaction to preclinical data on a long-acting version of lead drug nomacopan (PAS-nomacopan) that, it says, supports its use for back-of-the-eye diseases with less-frequent injections. More news on...
Lianluo Smart (NASDAQ: LLIT ) +94% . More news on: Lianluo Smart Limited, Cleveland BioLabs, Inc., Vir Biotechnology, Inc., Stocks on the move, , Read more ...
NEW YORK and LONDON, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announces new preclini...
Thinly traded nano cap Akari Therapeutics ( AKTX +10.4% ) is up on more than a 6x surge in volume on the heels of interim data from a Phase 3 clinical trial, CAPSTONE , evaluating Coversin (nomacopan) in complement inhibitor naïve, transfusion-dependent paroxysmal nocturnal hemoglo...
Phase III interim data on the first eight PNH patients who were all transfusion dependent at entry to the CAPSTONE trial show that all four patients randomized to nomacopan were transfusion independent for the first six months of treatment while all four patients on standard of care (SOC) ...
Intra-Cellular Therapies (NASDAQ: ITCI ) +89% after Caplyta approved by FDA. More news on: Intra-Cellular Therapies, Inc., Cincinnati Bell Inc., Seadrill Limited, Stocks on the move, Read more ...
Akari Therapeutics (NASDAQ: AKTX ) is up 7% premarket on announcing that the FDA IND is open for its multicenter Phase III study for the treatment of pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) with nomacopan, allowing clinical sit...
NEW YORK and LONDON, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announces that a ...
Omeros (OMER) is nearing the launch of its potential blockbuster, Narsoplimab. The drug's first target is HSCT-TMA. The company expects to receive FDA approval in late-2020. This document is intended to review the competitive landscape of Narsoplimab in HSCT-TMA. This is in no way a thorou...
Topline data from an initial six-subject cohort in an open-label, single-arm Phase 2 clinical trial evaluating Regeneron Pharmaceuticals' (NASDAQ: REGN ) pozelimab (REGN3918) in patients with paroxysmal nocturnal hemoglobinuria (PNH) showed a positive effect. More news on: Regene...
News, Short Squeeze, Breakout and More Instantly...
Akari Therapeutics Plc Company Name:
AKTX Stock Symbol:
NASDAQ Market:
Akari Therapeutics Plc Website:
Interim CEO employment contract consists solely of equity compensation Samir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement BOSTON and LONDON, June 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotec...
BOSTON and LONDON, June 04, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, today announced the successful initial closing of a private placement financing round. This transaction is ...
Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEO Plan for Prioritization of Peak Bio’s ADC Cancer Therapeutic Platform Technology and Akari’s PAS-nomacopan fo...